ReproCELLorp (TSE:4978) Other Stockholders Equity: 円157 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4978 ReproCELL Incorp TSE:4978
53 GF Score
Price 円125.00
GF Value 円156.83
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is ReproCELLorp Other Stockholders Equity?

ReproCELLorp TSE:4978 -1.57% 53 Other Stockholders Equity is 円157 Mil as of Mar. 2026. GuruFocus rates TSE:4978 with a GF Score™ of 53/100 and a GF Value™ of 円156.83 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ReproCELLorp's Other Stockholders Equity for the quarter that ended in Mar. 2026 was 円157 Mil.

ReproCELLorp's quarterly Other Stockholders Equity increased from Sep. 2025 (円171 Mil) to Dec. 2025 (円257 Mil) but then declined from Dec. 2025 (円257 Mil) to Mar. 2026 (円157 Mil).

ReproCELLorp's annual Other Stockholders Equity declined from Mar. 2024 (円157 Mil) to Mar. 2025 (円-6 Mil) but then increased from Mar. 2025 (円-6 Mil) to Mar. 2026 (円157 Mil).

ReproCELLorp Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ReproCELLorp's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ReproCELLorp Other Stockholders Equity Chart

ReproCELLorp Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.67 -13.82 157.11 -6.24 157.11

ReproCELLorp Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.24 -27.31 170.62 256.68 157.11
TSE:4978
53GF Score
ReproCELL Incorp TSE:4978
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ReproCELLorp Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of 円157 Mil mean?
ReproCELLorp (TSE:4978) has a Other Stockholders Equity of 円157 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ReproCELLorp and its competitors.
Is ReproCELLorp's Other Stockholders Equity too high?
ReproCELLorp's current Other Stockholders Equity is 円157 Mil. Overall, ReproCELLorp has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ReproCELLorp's Other Stockholders Equity compare to VRTX and REGN?
ReproCELLorp's Other Stockholders Equity of 円157 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ReproCELLorp and its competitors. ReproCELLorp's current Other Stockholders Equity is 円157 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ReproCELLorp stock overvalued right now?
Based on GuruFocus' analysis, ReproCELLorp (TSE:4978) is currently considered Modestly Undervalued. The stock's GF Value™ is 円156.83, compared to a current price of 円125.00 — trading 20.3% below its estimated fair value. The current Other Stockholders Equity is 円157 Mil. ReproCELLorp's overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For ReproCELLorp (TSE:4978), the current Other Stockholders Equity is 円157 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ReproCELLorp (TSE:4978) Overvalued in 2026?

Based on GuruFocus' analysis, ReproCELLorp stock appears to be undervalued. The current stock price of 円125.00 is trading 20.3% below its estimated GF Value™ of 円156.83. GuruFocus considers ReproCELLorp to be Modestly Undervalued.

Key valuation signals for TSE:4978:

  • Other Stockholders Equity: 円157 Mil
  • GF Value™: 円156.83 vs. price of 円125.00 (20.3% below fair value)
  • GF Score™: 53/100 with 3 warning signs

No single metric tells the full story. See the TSE:4978 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ReproCELLorp Business Description

Address KDX Shin-Yokohama 381 Bldg. 9F, 3-8-11, Shin-Yokohama, Kohoku-ku, Kanagawa, Yokohama, JPN, 222-0033
ReproCELL Incorp is one of the leading stem cell research company in Japan. The company provides stem cell services, predictive drug discovery services, tissue services, and molecular services.
53GF Score

Get the complete analysis for TSE:4978

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円125.00
Price
円156.83
GF Value